Select Your Region
Global
A study to look at how well the drug called atezolizumab works (and how safe atezolizumab is) to treat different types of cancer in the real world, outside of controlled clinical trials
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Cancer
- Lung Cancer
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Bladder Cancer
- Urothelial Carcinoma
- Hepatocellular Carcinoma (HCC)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Active, not recruiting
This trial runs in
Cities
- Achrafieh
- Ahmedabad
- Aix-en-Provence
- Alba Iulia
- albertville
- Alessandria
- Alexandria Governorate
- Almería
- Amsterdam
- Angers
- annecy
- Antony
- Arizona
- Arkhangel'sk
- Avignon
- Avon
- Badajoz
- Barcelona
- Barnaul
- Barnet
- Bath
- Bayrut
- Beirut
- Bengaluru
- Beograd
- Besançon
- Bielsko-Biała
- Birmingham
- Bordeaux
- bri
- București
- Budapest
- Buenos Aires
- Burgas
- Burgos
- Burnley
- Bydgoszcz
- Bystra
- Béziers
- Cagliari
- Cairo Governorate
- Cali
- Camaiore
- Cambridge
- Campania
- Cardiff
- Catania
- Chambéry
- chandigarh
- Ciudad de México
- Clermont-Ferrand
- Cluj-Napoca
- Coimbra
- Coppito
- Cottingham
- Cáceres
- Córdoba
- Debrecen
- Eaubonne
- Eindhoven
- Elbląg
- England
- figanieres
- Firenze
- Florence
- Genoa
- Giza Governorate
- Gleize
- Gliwice
- Granada
- Grudziądz
- Guildford
- Harrow
- Hazmiyeh
- Huddersfield
- Hyderabad
- Jabal Lubnan
- Jaén
- Kaluga
- kaluga-oblast
- Karachi
- Kaunas
- Kazan
- keighley
- Klagenfurt am Wörthersee
- kochi
- Krasnoyarsk
- Krems an der Donau
- La Florida
- La Laguna
- Lahore
- Le Coudray
- Le Mans
- le-chatenet-en-dognon
- Lecce
- Leeds
- Legnago
- León
- Lido di Camaiore
- Lille
- Limoges
- Lisboa
- Lisbon
- Ljubljana
- London
- Lorient
- Lublin
- Lugo
- Lyon
- Macerata
- Madrid
- Maidstone
- Majadahonda
- Manchester
- Manila
- Maribor
- Marseille
- Mataró
- Mechelen
- Medellín
- Meldola
- Messina
- Middlesbrough
- Milano
- Modena
- Monterrey
- Moscow
- Moscow Oblast
- Mumbai
- Muscat
- Napoli
- Newcastle upon Tyne
- Nottingham
- Nîmes
- Oostende
- Osijek
- Otwock
- Ourense
- Oxford
- Palermo
- Pamplona
- Panagyurishte
- Paris
- Pasay
- Pleven
- Ploiești
- Plovdiv
- poolacode
- Porto
- Poznań
- Pozuelo de Alarcón
- Preston
- Providencia
- Pécs
- Quezon City
- Reggio Calabria
- Reims
- Rionero In Vulture
- Roma
- Rosario
- Ruse
- Sabadell
- Saint Petersburg
- Saint-Nazaire
- Saint-Priest-en-Jarez
- Saint-Quentin
- San Cristóbal de La Laguna
- San Pedro Garza García
- San Sebastián de los Reyes
- Sankt-Peterburg
- Santa Cruz de Tenerife
- Santa Rosa
- Santiago de Compostela
- Sarreguemines
- Sassari
- Segovia
- Senhora da Hora
- Sevilla
- Sheffield
- Shuwaikh Industrial
- Sib
- Singapore
- Sint-Truiden
- Sofia
- Sora
- St Priest En Jarez
- Stoke-on-Trent
- Surat
- Sutton
- Swindon
- São Paulo
- Tallinn
- Tartu
- Timișoara
- Torquay
- Toulouse
- Truro
- tver
- Törökbálint
- Ufa
- Vadodara
- Valence
- Valenciennes
- Valladolid
- Vannes
- Vantoux
- varanasi
- Varese
- Varna
- Verona
- Vicenza
- Vila Nova de Gaia
- Vilnius
- Vöcklabruck
- Wakefield
- wallington
- Warszawa
- Wels
- Wirral
- Wolverhampton
- Wrocław
- York
- yudino
- Yvoir
- Zaandam
- Zagreb
- Zaragoza
- Épagny-Metz-Tessy
- Łódź
- أبو ظبي
Trial Identifier:
NCT03782207 MO40653
Trial Summary
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
Hoffmann-La Roche
Sponsor
NCT03782207,MO40653
Trial Identifier
All
Gender
≥18 Years
Age
No
Healthy Volunteers
How does the IMreal study work?
This is an ‘observational’ study collecting real-world data. This means that all treatment decisions will be made by your regular doctors and all of the data will be collected from your medical records.
This study is recruiting patients with different types of cancer to test how different cancers respond to therapy with atezolizumab. Currently the study is looking for patients with urothelial cancer, often called bladder cancer, lung cancer and a type of liver cancer called hepatocellular carcinoma (HCC).
Any patients with urothelial cancer must have been treated with chemotherapy before joining the study.
Patients with lung cancer will join one of four different groups based on their specific type of lung cancer:
- Patients with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has previously been treated with chemotherapy
- Patients with a special subset of NSCLC called non-squamous NSCLC that has not been treated before
- Patients with NSCLC (with high levels of a protein called PD-L1) that has not been treated before
- Patients with a type of lung cancer called small cell lung cancer (SCLC), that has not been treated before
Any patients with HCC must have unresectable disease (that cannot be completely removed with surgery), locally advanced or metastatic disease (that has spread to other parts of the body). They should not have received any previous systemic treatment (a kind of treatment that travels through the blood and can reach and affect cells all over the body) for their disease before.
The purpose of this study is to see how treatment with atezolizumab works in real life when doctors decide that it is the best treatment option for their patients. Another aim is to see how safe atezolizumab is in real life. This will help doctors to know how better to use atezolizumab to treat their patients.
How do I take part in this study?
To be able to take part in this study, you must have been diagnosed with urothelial cancer, lung cancer (either NSCLC or SCLC) or HCC that has spread to other parts of the body. Your doctor must have decided that atezolizumab is the most suitable treatment for your cancer. You must not have previously been treated with atezolizumab.
If you think this study may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to join this study, he/she will give you all the information you need to make your decision about taking part.
If you would like to join the study, you will need to agree to your data being collected from your medical records. The data that will be collected will be kept in your medical records whether or not you choose to join the study.
What treatment will I be given if I join this study?
In order to join the study, you and your doctor must have decided that atezolizumab is the best treatment for your cancer. Therefore, you will be given atezolizumab whether or not you decide to take part in the study. The dose and length of treatment will be decided by your doctor and the guidelines for your area, and will not be affected by whether or not you decide to join the study. Your doctor will give you atezolizumab on its own or together with other medications, depending on clinical guidelines.
How often will I be seen in follow-up appointments, and for how long?
You will be given treatment in exactly the same way as you would be if you did not join the trial. This means that you will be given atezolizumab for as long as your doctor thinks it can help you and you will not have any extra hospital or clinic visits. You or your doctor are free to decide to stop this treatment at any time. After stopping treatment, you will still be seen regularly by your doctor as part of your regular care.
What happens if I am unable to take part in this study?
If this study is not suitable for you, you will not be able to take part. However, this will not affect the treatment that you are given by your doctor. You will not lose access to any of your regular care.
For more information about this study see the For Expert tab on the specific ForPatient page or follow this link to ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03782207
Trial-identifier: NCT03782207
Trial Summary
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
Hoffmann-La Roche
Sponsor
NCT03782207,MO40653
Trial Identifier
Atezolizumab
Treatments
Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
Condition
Official Title
A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Patient must have one of the following confirmed diagnoses for which atezolizumab is locally approved in the SmPC: (1) As monotherapy for the treatment of adult patients with locally advanced/metastatic UC after prior platinum-containing chemotherapy (Cohort 1 LOT2+mUC) or (2) As monotherapy for the treatment of adult patients with locally advanced/metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab (Cohort 2 LOT2+NSCLC) or (3) In combination with bevacizumab, paclitaxel and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC. Patients with EGFR activating mutations or ALK- positive tumour mutations should also have received targeted therapy (Cohort 3 LOT1 NSCLC) or (4) In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (Cohort 4 LOT1 ES-SCLC) or (5) As a monotherapy, for the treatment of metastatic NSCLC with high PD-L1 expression, previously untreated (Cohort 5 LOT1 NSCLC) or (6) In combination with bevacizumab for unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy (Cohort 6 LOT1 HCC) .
- Patient is administered atezolizumab therapy for the first time.
- Decision to administer atezolizumab must be made and documented prior to inclusion into the study and must follow local clinical practice.
Exclusion Criteria
- Patients not receiving treatment for a disease with atezolizumab according to standard of care and in line with the current summary of product characteristics (SPC) or local labelling. Cisplatin ineligible patients receiving atezolizumab LOT1 for the treatment of locally advanced/metastatic UC patients will be excluded
- Concomitant anti-cancer therapy at the time of starting atezolizumab on the index date not part of locally approved combination therapy with atezolizumab.
- Treatment with atezolizumab as part of a clinical trial or for compassionate use as part of a pre-approval or compassionate use program.
- Patients not receiving atezolizumab, but a biosimilar or non-original biologic.
For the latest version of this information please go to www.forpatients.roche.com